David Ebsworth – Chairman
David has been Chairman of Actimed Therapeutics since April 2018. He has also invested in the Company. Dr Ebsworth has 40 years of experience in the Healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and past global head of the Pharmaceutical Division of Bayer AG.
Dr Ebsworth has chaired numerous private and public pharmaceutical companies and also served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. Dr Ebsworth currently serves as Chairman of Verona Pharma PLC which is listed on both the AIM and Nasdaq stock exchanges.
Glyn Parkin – CEO
Glyn has been CEO since September 2017. He has thirty-seven years’ pharmaceutical industry experience. Glyn was Senior VP and Global Head of Therapeutic Area Metabolism at Boehringer Ingelheim GmbH where he successfully brought the Companies’ first diabetes products, linagliptin and empagliflozin, from development to market. Prior to this, at Eli Lilly and Company, his roles included Chief Marketing Officer EMEA & Russia/CIS, before which he formed and led the USA Diabetes Business Unit and the USA Neuroscience Business Unit, and prior to this he served on the UK board as Director, Specialty Business and Strategic Planning (business units in diabetes, growth disorders, oncology, neurology, and interventional cardiology) where he led several major drug launches. Glyn is a graduate of Cardiff University where he studied economics and industrial relations, and of Cranfield School of Management where he gained his MBA. As well as serving on the Board of Actimed Therapeutics, he is Chairman of the Board at Harley Street Concierge.
Andrew Coats MBA, DSc, DM, scientific founder and board director, Lone Star Heart. Chairman of ACT Ventures, previously of Myotec and PsiOxus. Experienced company director and a founder of Actimed Therapeutics.
Frank Misselwitz, MD, PhD, currently Corporate Vice President and Therapeutic Area Head in clinical development at Bayer AG. With a background in academia and industry, he has extensive experience of successful drug development at Bayer.
Hugh Jackson of Jacksons Accountants is the Board Secretary and CFO/Company Secretary.